CEL-SCI (AMEX:CVM) has potential upside of 859.7% based on a current price of $0.73 and analysts' consensus price target of $7.00. The stock should find initial resistance at its 50-day moving average (MA) of $0.74 and further resistance at its 200-day MA of $1.77.
In the past 52 weeks, CEL-SCI share prices have been bracketed by a low of $0.53 and a high of $3.90 and are now at $0.73, 38% above that low price. The 200-day and 50-day moving averages have moved 2.35% lower and 2.01% lower over the past week, respectively.
CEL-SCI Corporation researches and develops certain drugs and vaccines. The Company's Multikine is being tested to determine if it is effective in improving the immune response of cancer patients. CEL-SCI is also developing other products. The Company is currently targeting diseases such as AIDS, herpes simplex, malaria, tuberculosis, prostate cancer, and breast cancer.
News 
Market Data 
Discover 
